Which one is better long-term investment if bought now unh or nvo nordisk

``` The deep research logic is organized as follows: Okay, let's tackle this question. The user is asking whether UnitedHealth Group (UNH) or Novo Nordisk (NVO) is a better long-term investment if bought now. First, I need to look at the data provided in the references and background. Starting with the P/E ratios, UNH has a lower P/E of 11.26 compared to NVO's 19.4. That suggests UNH might be undervalued relative to NVO. The P/S ratio for UNH is 0.68, which is much lower than NVO's 7.07. This indicates UNH is cheaper in terms of sales. The P/B ratio for UNH is 2.62, while NVO's is 14.65, showing UNH is also cheaper on a book value basis. So, from a valuation standpoint, UNH looks more attractive. Next, looking at revenue and net income growth. UNH's revenue growth is 10% YoY, and net income growth is 6.3%, which is positive but not as high as NVO's 18% revenue growth and 13% net income growth. However, UNH's 5-year CAGR for revenue is 11.7%, which is better than NVO's 25.08%? Wait, no, NVO's 5-year revenue CAGR is 25.08%, which is higher. But UNH's net income CAGR is negative (-0.85%), while NVO's is 26.54%. That's a big difference. So NVO has stronger historical growth in net income. Dividend yields: UNH has a 2.79% yield, NVO 2.31%. UNH has a longer dividend growth streak (15 years vs. 5 years for NVO). Dividend sustainability is important for long-term investors, and UNH's longer streak might indicate more stability. Debt-to-equity ratio isn't available for either, but UNH has a negative free cash flow of -$3 billion in Q1 2025, while NVO's is -$218.86 million. Negative free cash flow could be a concern, but UNH's is much larger in magnitude. However, UNH's debt situation might be more complex given their recent $3 billion debt issuance mentioned in the news. NVO's debt-to-equity ratio is 0.72, which is moderate, but UNH's isn't provided. Looking at the news, UNH has leadership changes, a suspended 2025 outlook, and challenges in Medicare Advantage. NVO has partnerships expanding their weight loss drug sales, which could be a growth driver. UNH's market cap is larger, but NVO's revenue growth is higher. The user is interested in blue-chip stocks and has a short-term horizon, but the question is about long-term. UNH's stability and dividend might appeal, while NVO's growth potential in the obesity market could be a plus. However, UNH's valuation metrics are more favorable, and their dividend track record is stronger. I need to structure this into a conclusion, then detailed analysis with tables, and include the visualizations as per the requirements. Make sure to cite the references correctly and use the provided data. Also, the user prefers blue-chip stocks, so UNH's size and stability might be a factor. But NVO's growth in revenue and net income could offer higher returns. Need to balance both aspects. ``` **Conclusion** UnitedHealth Group (UNH) and Novo Nordisk (NVO) present distinct profiles for long-term investment, with UNH offering **greater valuation affordability** and **dividend stability**, while NVO boasts **stronger growth momentum** and **expansion potential in the obesity market**. Based on the data, **UNH is the better long-term choice** for its **undervaluation relative to peers**, **consistent dividend history**, and **resilient business model**, despite near-term challenges. NVO, however, holds **high-growth appeal** for investors prioritizing innovation in diabetes and weight-loss treatments. --- ### 📊 **Key Metrics Comparison** | Metric | UNH (2025Q1) | NVO (2025Q1) | |----------------------------|----------------------------------|----------------------------------| | **P/E Ratio (TTM)** | 11.26 | 19.4 | | **P/S Ratio (TTM)** | 0.68 | 7.07 | | **P/B Ratio** | 2.62 | 14.65 | | **Revenue Growth (YoY)** | 10% | 18% | | **Net Income Growth (YoY)**| 6.3% | 13% | | **5-Year Revenue CAGR** | 11.7% | 25.08% | | **5-Year Net Income CAGR** | -0.85% | 26.54% | | **Dividend Yield** | 2.79% | 2.31% | | **Dividend Growth Duration**| 15 years | 5 years | |code|Ticker|Name|Date|P/E(TTM)|P/S|Price to Book Ratio|market_code| |---|---|---|---|---|---|---|---| |NVO|NVO.N|Novo Nordisk|20240702|49.294967|16.61556906970734|44.49310535917268|169| |UNH|UNH.N|UnitedHealth Group|20240702|29.853047|1.154216842019421|5.28992086295681|169| |NVO|NVO.N|Novo Nordisk|20240703|47.87797|16.137949900057755|43.21413862937692|169| |UNH|UNH.N|UnitedHealth Group|20240703|29.35274|1.134873331601024|5.201267123382129|169| |NVO|NVO.N|Novo Nordisk|20240705|49.08262|16.543994403675022|44.303283046477944|169| |UNH|UNH.N|UnitedHealth Group|20240705|29.240096|1.130518146021792|5.181306760459925|169| |NVO|NVO.N|Novo Nordisk|20240708|49.323948|16.6253373557195|44.52111192989814|169| |UNH|UNH.N|UnitedHealth Group|20240708|29.319785|1.1335992081602912|5.195427655505952|169| |NVO|NVO.N|Novo Nordisk|20240709|48.413797|16.318558222294605|43.69777088273609|169| |UNH|UNH.N|UnitedHealth Group|20240709|29.485756|1.1400161571254361|5.224837339173242|169| --- ### 📊 **Analysis** #### 1. **Valuation: UNH is Undervalued** - UNH trades at **11.26x P/E vs. NVO’s 19.4x**, making it cheaper relative to earnings. - UNH’s **P/S ratio (0.68)** is **82% cheaper** than NVO’s (7.07), reflecting its dominance in healthcare services. - UNH’s **P/B ratio (2.62)** is **83% cheaper** than NVO’s (14.65), indicating better asset utilization. #### 2. **Growth: NVO Leads in Innovation** - NVO’s **5-year revenue CAGR (25.08%)** and **net income CAGR (26.54%)** surpass UNH’s (11.7% and -0.85%). - NVO’s **obesity drug (Wegovy)** dominates the market, with partnerships like **WeightWatchers** driving **18% YoY revenue growth**. - UNH’s **Medicare Advantage challenges** and **suspended 2025 outlook** weigh on its growth trajectory. #### 3. **Dividends: UNH Offers Stability** - UNH’s **2.79% dividend yield** vs. NVO’s 2.31% provides **higher income** for long-term holders. - UNH has a **15-year dividend growth streak** , while NVO’s streak is only **5 years**. - UNH’s **$3 billion share buyback** signals confidence in its financial health, despite near-term debt concerns . #### 4. **Risks: UNH Faces Regulatory Headwinds** - UNH’s **$3 billion debt issuance** and **44.6% financial leverage** raise liquidity risks. - UNH’s **Medicare Advantage losses** and **leadership shuffle** could disrupt its long-term strategy. - NVO’s **dependence on obesity drugs** exposes it to regulatory risks and market saturation. --- ### 📊 **Conclusion** For **long-term stability** and **income generation**, UNH’s **undervaluation** and **dividend resilience** make it the superior choice. NVO, while **growth-oriented**, carries higher risks due to its reliance on a single product (Wegovy) and shorter dividend history. UNH’s **blue-chip credentials** and **market leadership** in healthcare services align with your preference for **blue-chip stocks** and **short-term technical analysis**. **Final Pick: UNH**